FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:C19orf10-MAP2K3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: C19orf10-MAP2K3
FusionPDB ID: 11155
FusionGDB2.0 ID: 56252
HgeneTgene
Gene symbol

C19orf10

MAP2K3

Gene ID

56005

5606

Gene namemyeloid derived growth factormitogen-activated protein kinase kinase 3
SynonymsC19orf10|EUROIMAGE1875335|IL25|IL27|IL27w|R33729_1|SF20MAPKK3|MEK3|MKK3|PRKMK3|SAPKK-2|SAPKK2
Cytomap

19p13.3

17p11.2

Type of geneprotein-codingprotein-coding
Descriptionmyeloid-derived growth factorUPF0556 protein C19orf10interleukin 27 working designationinterleukin-25stromal cell-derived growth factor SF20dual specificity mitogen-activated protein kinase kinase 3MAP kinase kinase 3MAPK/ERK kinase 3MAPKK 3MEK 3SAPK kinase 2stress-activated protein kinase kinase 2
Modification date2020031320200327
UniProtAcc.

P46734

Main function of 5'-partner protein: FUNCTION: Dual specificity kinase. Is activated by cytokines and environmental stress in vivo. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14. {ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8622669}.
Ensembl transtripts involved in fusion geneENST idsENST00000262947, ENST00000599630, 
ENST00000316920, ENST00000361818, 
ENST00000534743, ENST00000342679, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score4 X 4 X 4=645 X 5 X 3=75
# samples 55
** MAII scorelog2(5/64*10)=-0.356143810225275
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: C19orf10 [Title/Abstract] AND MAP2K3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: C19orf10 [Title/Abstract] AND MAP2K3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)C19orf10(4659942)-MAP2K3(21201724), # samples:1
Anticipated loss of major functional domain due to fusion event.C19orf10-MAP2K3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
C19orf10-MAP2K3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneC19orf10

GO:0001938

positive regulation of endothelial cell proliferation

25581518

HgeneC19orf10

GO:0045766

positive regulation of angiogenesis

25581518

TgeneMAP2K3

GO:0045860

positive regulation of protein kinase activity

11980910

TgeneMAP2K3

GO:0045893

positive regulation of transcription, DNA-templated

11980910



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:4659942/chr17:21201724)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across C19orf10 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MAP2K3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000262947C19orf10chr194659942-ENST00000342679MAP2K3chr1721201724+2483478361472478

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000262947ENST00000342679C19orf10chr194659942-MAP2K3chr1721201724+0.0035552430.99644476

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for C19orf10-MAP2K3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
C19orf10chr194659942MAP2K3chr1721201724478147PLKTEEFEVTKTAGKSKRKKDLRISC

Top

Potential FusionNeoAntigen Information of C19orf10-MAP2K3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C19orf10-MAP2K3_4659942_21201724.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:08KTAGKSKRK0.99470.7491019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:08VTKTAGKSK0.98850.8405817
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A74:09KTAGKSKRK0.95320.50321019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A74:11KTAGKSKRK0.95320.50321019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A74:03KTAGKSKRK0.95320.50321019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:08KTAGKSKRKK0.99070.77121020
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A66:01EVTKTAGKSK0.97680.654717
C19orf10-MAP2K3chr194659942chr1721201724478HLA-B50:02EEFEVTKTAG0.84360.6819414
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:01KTAGKSKRK0.99510.81961019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:01VTKTAGKSK0.98750.911817
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A74:01KTAGKSKRK0.95320.50321019
C19orf10-MAP2K3chr194659942chr1721201724478HLA-A30:01KTAGKSKRKK0.99080.84841020

Top

Potential FusionNeoAntigen Information of C19orf10-MAP2K3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
C19orf10-MAP2K3_4659942_21201724.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0435TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0813TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0815TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0830TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0902TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-0902KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1130TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1367TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1385TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1386TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1402TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1402KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1403TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1409TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1419TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1424TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1440TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1441TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1441KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1446TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1446KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1447TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1451TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1451KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1467TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1477TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1489TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1489KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1494TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1494KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB1-1498TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0101TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0101KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0101EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0101LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0102TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0102KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0102EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0102LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0103TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0103KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0103EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0103LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0104TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0104KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0104EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0104LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0105TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0105KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0105EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0105LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0108NTEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0108NKTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0108NEEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0108NLKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0111TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0111KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0111EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0111LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0112TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0112KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0112EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0112LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0113TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0113KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0113EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0113LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0114TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0114KTEEFEVTKTAGKSK217
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0114EEFEVTKTAGKSKRK419
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0114LKTEEFEVTKTAGKS116
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0203TEEFEVTKTAGKSKR318
C19orf10-MAP2K3chr194659942chr1721201724478DRB5-0203KTEEFEVTKTAGKSK217

Top

Fusion breakpoint peptide structures of C19orf10-MAP2K3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2353FEVTKTAGKSKRKKC19orf10MAP2K3chr194659942chr1721201724478

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of C19orf10-MAP2K3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2353FEVTKTAGKSKRKK-8.55667-8.74867
HLA-B14:023BVN2353FEVTKTAGKSKRKK-3.49457-4.25557
HLA-B52:013W392353FEVTKTAGKSKRKK-7.26725-7.45925
HLA-B52:013W392353FEVTKTAGKSKRKK-4.01461-4.77561
HLA-A24:025HGA2353FEVTKTAGKSKRKK-7.65911-8.42011
HLA-A24:025HGA2353FEVTKTAGKSKRKK-7.10204-7.29404
HLA-B44:053DX82353FEVTKTAGKSKRKK-7.5556-8.3166
HLA-B44:053DX82353FEVTKTAGKSKRKK-2.76159-2.95359

Top

Vaccine Design for the FusionNeoAntigens of C19orf10-MAP2K3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
C19orf10-MAP2K3chr194659942chr17212017241019KTAGKSKRKAAACAGCAGGAAAATCCAAGAGGAAGA
C19orf10-MAP2K3chr194659942chr17212017241020KTAGKSKRKKAAACAGCAGGAAAATCCAAGAGGAAGAAGG
C19orf10-MAP2K3chr194659942chr1721201724414EEFEVTKTAGAGGAATTTGAAGTGACCAAAACAGCAGGAA
C19orf10-MAP2K3chr194659942chr1721201724717EVTKTAGKSKAAGTGACCAAAACAGCAGGAAAATCCAAGA
C19orf10-MAP2K3chr194659942chr1721201724817VTKTAGKSKTGACCAAAACAGCAGGAAAATCCAAGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
C19orf10-MAP2K3chr194659942chr1721201724116LKTEEFEVTKTAGKSTGAAAACTGAGGAATTTGAAGTGACCAAAACAGCAGGAAAATCCA
C19orf10-MAP2K3chr194659942chr1721201724217KTEEFEVTKTAGKSKAAACTGAGGAATTTGAAGTGACCAAAACAGCAGGAAAATCCAAGA
C19orf10-MAP2K3chr194659942chr1721201724318TEEFEVTKTAGKSKRCTGAGGAATTTGAAGTGACCAAAACAGCAGGAAAATCCAAGAGGA
C19orf10-MAP2K3chr194659942chr1721201724419EEFEVTKTAGKSKRKAGGAATTTGAAGTGACCAAAACAGCAGGAAAATCCAAGAGGAAGA

Top

Information of the samples that have these potential fusion neoantigens of C19orf10-MAP2K3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCC19orf10-MAP2K3chr194659942ENST00000262947chr1721201724ENST00000342679TCGA-FX-A3TO

Top

Potential target of CAR-T therapy development for C19orf10-MAP2K3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to C19orf10-MAP2K3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to C19orf10-MAP2K3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource